Mortality in Schizophrenia: Clinical and serological predictors

Schizophrenia Bulletin

Volumn 40, Issue 4, 2014, Pages 796-803

  Dickerson, Faith ^a   Stallings, Cassie ^a   Origoni, Andrea ^a   Schroeder, Jennifer ^b   Khushalani, Sunil ^a   Yolken, Robert ^c  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b Schroeder Statistical Consulting   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cigarette smoking; Epstein Barr virus; premature death

Indexed keywords

ANTIBODY; CLOZAPINE; PROTOZOON ANTIBODY; VIRUS ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CAUCASIAN; CAUSE OF DEATH; CLINICAL EVALUATION; COGNITIVE DEFECT; COHORT ANALYSIS; ENDOCRINE DISEASE; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; SEROLOGY; SMOKING; SMOKING CESSATION; STANDARDIZED MORTALITY RATIO; TOXOPLASMA GONDII; UROGENITAL TRACT DISEASE; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; IMMUNOLOGY; MIDDLE AGED; PREMATURE MORTALITY; PSYCHOLOGY; TOXOPLASMA; TOXOPLASMOSIS; UNITED STATES;

ADULT; ANTIBODIES, PROTOZOAN; ANTIBODIES, VIRAL; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; MORTALITY, PREMATURE; PROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; TOXOPLASMA; TOXOPLASMOSIS; UNITED STATES;

EID: 84902595559     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt113     Document Type: Article

References (43)

1. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131.
2. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25:83-88.
3. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res. 2011;131:101-104.
4. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115-1121.
5. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170:324-333.
6. Suvisaari J, Partti K, Perälä J, et al. Mortality and its determinants in people with psychotic disorder. Psychosom Med. 2013;75:60-67.
7. Kilbourne AM, Morden NE, Austin K, et al. Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifable risk factors. Gen Hosp Psychiatry. 2009;31:555-563.
8. Brown S, Mitchell C. Predictors of death from natural causes in schizophrenia: 10-year follow-up of a community cohort. Soc Psychiatry Psychiatr Epidemiol. 2012;47:843-847.
9. Kelly DL, McMahon RP, Wehring HJ, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull. 2011;37:832-838.
10. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66:183-194; quiz 147, 273-184.
11. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620-627.
12. Dickerson F, Yu A, Dalcin A, et al. Cigarette smoking and health characteristics in individuals with serious mental illness enrolled in a behavioral weight loss trial. J Dual Diagn. 2013;9:1-8.
13. Richard MD, Brahm NC. Schizophrenia and the immune system: pathophysiology, prevention, and treatment. Am J Health Syst Pharm. 2012;69:757-766.
14. Arias I, Sorlozano A, Villegas E, et al. Infectious agents associated with schizophrenia: a meta-analysis. Schizophr Res. 2012;136:128-136.
15. Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev. 1995;8:131-145.
16. Dickerson F, Boronow J, Stallings C, Origoni A, Yolken R. Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality. Schizophr Bull. 2007;33:737-740.
17. First M, Gibbon M, Spitzer RL, Williams JBW. User's Guide for the SCID-I, Structured Clinical Interview for DSM IV Axis I Disorders. New York: Biometrics Research; 1996.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
19. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310-319.
20. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Ruslanova I, Yolken RH. Association of serum antibodies to herpes simplex virus 1 with cognitive defcits in individuals with schizophrenia. Arch Gen Psychiatry. 2003;60:466-472.
21. Centers for Disease Control. Deaths in the US due to natural causes. www.cdc.gov/nchs/faststats/diabetes.htm. Accessed November 28, 2013.
22. US Census Bureau. Population counts for racial and gender groups. www.census.gov/prod/www/abs/p25.html. Accessed November 28, 2012.
23. Washington State Health Department. Guidelines for using confdence intervals for public health assessment. www.doh. wa.gov/Documents/5500/ ConfntGuide.pdf. Accessed July 13, 2012.
24. Kahn HA, Sempos CT. Statistical Methods in Epidemiology. Oxford UK: Oxford University Press; 1989.
25. Ziedonis D, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res. 2008;10:1691-1715.
26. Prochaska JJ. Integrating tobacco treatment into mental health settings. JAMA. 2010;304:2534-2535.
27. Prochaska JJ. Smoking and mental illness-breaking the link. N Engl J Med. 2011;365:196-198.
28. Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol. 2008;22:883-896.
29. Zabala López S, Vicario JM, Lerín FJ, Fernández A, Pérez G, Fonseca C. Epstein-Barr virus myocarditis as the frst symptom of infectious mononucleosis. Intern Med. 2010;49:569-571.
30. Hasegawa D, Kaji M, Takeda H, et al. Fatal degeneration of specialized cardiac muscle associated with chronic active Epstein-Barr virus infection. Pediatr Int. 2009;51:846-848.
31. Sabbatani S, Manfredi R, Ortolani P, Trapani FF, Viale P. Myopericarditis during a primary Epstein-Barr virus infection in an otherwise healthy young adult. An unusual and insidious complication. Case report and a 60-year literature review. Infez Med. 2012;20:75-81.
32. Mavrogeni S, Spargias K, Bratis C, Kolovou G, Papadopoulou E, Pavlides G. EBV Infection as a cause of VT: evaluation by CMR. JACC Cardiovasc Imaging. 2011;4:561-562.
33. Hebert MM, Yu C, Towbin JA, Rogers BB. Fatal Epstein-Barr virus myocarditis in a child with repetitive myocarditis. Pediatr Pathol Lab Med. 1995;15:805-812.
34. Ishikawa T, Zhu BL, Li DR, Zhao D, Maeda H. Epstein-Barr virus myocarditis as a cause of sudden death: two autopsy cases. Int J Legal Med. 2005;119:231-235.
35. Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol. 2010;49:151-157.
36. Hui EP, Taylor GS, Jia H, et al. Phase I trial of recombinant modifed vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 2013;73:1676-1688.
37. Bouza E, Giannella M, Torres MV, et al. Herpes simplex virus: a marker of severity in bacterial ventilator-associated pneumonia. J Crit Care. 2011;26:432, e431-436.
38. Costa C, Sidoti F, Saldan A, et al. Clinical impact of HSV-1 detection in the lower respiratory tract from hospitalized adult patients. Clin Microbiol Infect. 2012;18:E305-E307.
39. Miller BJ, Graham KL, Bodenheimer CM, Culpepper NH, Waller JL, Buckley PF. A prevalence study of urinary tract infections in acute relapse of schizophrenia. J Clin Psychiatry. 2013;74:271-277.
40. Molander U, Arvidsson L, Milsom I, Sandberg T. A longitudinal cohort study of elderly women with urinary tract infections. Maturitas. 2000;34:127-131.
41. Høye A, Rezvy G, Hansen V, Olstad R. The effect of gender in diagnosing early schizophrenia-an experimental case simulation study. Soc Psychiatry Psychiatr Epidemiol. 2006;41:549-555.
42. Lahti M, Tiihonen J, Wildgust H, et al. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychol Med. 2012;42:2275-2285.
43. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.